I listened too.. nice summary Zoomie. The thing I find interesting is MGI knew these study results were coming must have anticipated they'd be good. AND still raised their full year guidance for Dacogen..This tells me they believe longer term survivial is a class effect and wiil be interpeted as such by specialists treating this disease. The fact is Dacogen is a better more potent version of Vidaza and even though Vidaza had a huge lead in the market Dacogen csught up and surpassed it in less than a year. IF and its a big if Vidaza should briefly lead again in market share DACOGEN will again catch up and surpass and the whole market for these drugs will have expanded. None of this takes into account ongoing trials for AML and solid tumors. Its gonna take 9 months of patience but its gonna be worth it. In the meantime buy some PHRM puts.